Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non‐small‐cell lung cancer in New Zealand

间变性淋巴瘤激酶 医学 肺癌 内科学 克里唑蒂尼 肿瘤科 碱性抑制剂 人口 一致性 ROS1型 铈替尼 癌症 腺癌 环境卫生 恶性胸腔积液
作者
Mark James McKeage,Sandar Tin Tin,Prashannata Khwaounjoo,Karen L. Sheath,Amanda Dixon‐McIver,Daniel Ng,Richard Sullivan,Laird Cameron,Philip Shepherd,George Robert Laking,Nicola J. Kingston,Magreet Strauss,Christopher A. Lewis,Mark Elwood,Donald Roy Love
出处
期刊:Internal Medicine Journal [Wiley]
卷期号:50 (6): 716-725 被引量:19
标识
DOI:10.1111/imj.14435
摘要

BACKGROUND: Lung cancer is a major cause of death in New Zealand. In recent years, targeted therapies have improved outcomes. AIM: To determine the uptake of anaplastic lymphoma kinase (ALK) testing, and the prevalence, demographic profile and outcomes of ALK-positive non-small-cell lung cancer (NSCLC), in New Zealand, where no national ALK-testing guidelines or subsidised ALK tyrosine kinase inhibitor (TKI) therapies are available. METHODS: A population-based observational study reviewed databases to identify patients presenting with non-squamous NSCLC over 6.5 years in northern New Zealand. We report the proportion tested for ALK gene rearrangements and the results. NSCLC samples tested by fluorescence in situ hybridisation were retested by next generation sequencing and ALK immunohistochemistry. A survival analysis compared ALK-positive patients treated or not treated with ALK TKI therapy. RESULTS: From a total of 3130 patients diagnosed with non-squamous NSCLC, 407 (13%) were tested for ALK gene rearrangements, and patient selection was variable and inequitable. Among those tested, 34 (8.4%) had ALK-positive NSCLC. ALK-positive disease was more prevalent in younger versus older patients, non-smokers versus smokers and in Māori, Pacific or Asian ethnic groups than in New Zealand Europeans. Fluorescence in situ hybridisation, ALK immunohistochemistry and next generation sequencing showed broad concordance for detecting ALK-positive disease under local testing conditions. Among patients with ALK-positive metastatic NSCLC, those treated with ALK TKI survived markedly longer than those not treated with ALK TKI (median overall survival 5.12 vs 0.55 years). CONCLUSION: Lung cancer outcomes in New Zealand may be improved by providing national guidelines and funding policy for ALK testing and access to subsidised ALK TKI therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
邵邵发布了新的文献求助20
1秒前
1秒前
jedeecn发布了新的文献求助30
1秒前
1秒前
2秒前
星星月完成签到 ,获得积分10
2秒前
希望天下0贩的0的应助被sttise采纳,获得10
2秒前
HungryAo完成签到,获得积分10
3秒前
3秒前
千千完成签到,获得积分10
3秒前
罗祁发布了新的文献求助10
4秒前
4秒前
6秒前
nini发布了新的文献求助10
6秒前
李美美完成签到 ,获得积分10
6秒前
Xoosi完成签到 ,获得积分10
6秒前
7秒前
8秒前
北风北风发布了新的文献求助10
9秒前
喜悦妙柏完成签到,获得积分10
9秒前
大模型的应助被落日晚风采纳,获得10
9秒前
大方元风发布了新的文献求助10
10秒前
11秒前
cherish完成签到,获得积分10
11秒前
逢考必过发布了新的文献求助10
11秒前
Lu发布了新的文献求助10
12秒前
淡淡听枫发布了新的文献求助30
12秒前
13秒前
星辰大海的应助被红莲墨生采纳,获得10
13秒前
貝壳完成签到 ,获得积分10
13秒前
chc完成签到,获得积分10
14秒前
369ninja发布了新的文献求助10
14秒前
14秒前
orixero的应助被坚定的采波采纳,获得10
14秒前
传奇3的应助被周周周采纳,获得10
16秒前
baihehuakai发布了新的文献求助10
17秒前
mouse发布了新的文献求助10
17秒前
18秒前
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817